Investigators observe an increase risk of meningioma in patient treated by CYPROTERONE ACETATE or other form of progestin. Investigatorsdiscribe caractéristics of meningioma and treatement of the patients follow up in CHRU of Brest
Retrospective study in CHRU of brest, the investigators selected patient with history of méningioma and treated by CYPROTERONE ACETATE, CHLORMADINONE ACETATE and NOMEGESTROL ACETATE essentially The investigators excluded patient with risk factor of meningioma added at hormonal treatment exposition The investigators discribe the caractéristique of patients: age, sex, duration of the treatment, the caractéristique of the meningioma: localization, grade, hormonal receptors, treatment by surgery or radiotherapy and changing after discontinuation of treatment
Study Type
OBSERVATIONAL
Enrollment
110
Département de Nutrition - CHRU de Brest
Brest, France
Diagnosis of meningiomas caracteristics
meningiomas caracteristics in patient treated with CYPROTERONE ACETATE or Progestin description
Time frame: 12 months
prescription status of progestogenic treatment
indications, duration of treatment, name and type of treatment
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.